Business Description
Jubilant Pharmova Ltd
ISIN : INE700A01033
Compare
Compare
Traded in other countries / regions
530019.India IPO Date
1995-05-05Description
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.26 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.67 | |||||
| Debt-to-EBITDA | 2.83 | |||||
| Interest Coverage | 2.27 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.42 | |||||
| Beneish M-Score | -2.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.8 | |||||
| 3-Year EBITDA Growth Rate | -18.5 | |||||
| 3-Year EPS without NRI Growth Rate | -30.8 | |||||
| 3-Year FCF Growth Rate | -61.1 | |||||
| 3-Year Book Growth Rate | 4.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 42.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 9.34 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.56 | |||||
| 9-Day RSI | 55.29 | |||||
| 14-Day RSI | 61.79 | |||||
| 6-1 Month Momentum % | 61.89 | |||||
| 12-1 Month Momentum % | 111.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.05 | |||||
| Quick Ratio | 1.37 | |||||
| Cash Ratio | 0.51 | |||||
| Days Inventory | 197.44 | |||||
| Days Sales Outstanding | 49.76 | |||||
| Days Payable | 128.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.43 | |||||
| Dividend Payout Ratio | 0.27 | |||||
| Forward Dividend Yield % | 0.43 | |||||
| 5-Year Yield-on-Cost % | 0.43 | |||||
| 3-Year Average Share Buyback Ratio | 0.2 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.76 | |||||
| Operating Margin % | 8.88 | |||||
| Net Margin % | 8.13 | |||||
| FCF Margin % | 1.08 | |||||
| ROE % | 10.21 | |||||
| ROA % | 4.86 | |||||
| ROIC % | 5.62 | |||||
| 3-Year ROIIC % | -29.14 | |||||
| ROC (Joel Greenblatt) % | 19.85 | |||||
| ROCE % | 9.53 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 33.1 | |||||
| Forward PE Ratio | 18.84 | |||||
| PE Ratio without NRI | 63.26 | |||||
| Shiller PE Ratio | 29.9 | |||||
| Price-to-Owner-Earnings | 164.08 | |||||
| PS Ratio | 2.69 | |||||
| PB Ratio | 3.35 | |||||
| Price-to-Tangible-Book | 9.47 | |||||
| Price-to-Free-Cash-Flow | 248.63 | |||||
| Price-to-Operating-Cash-Flow | 18.84 | |||||
| EV-to-EBIT | 23 | |||||
| EV-to-EBITDA | 16.19 | |||||
| EV-to-Revenue | 3.08 | |||||
| EV-to-FCF | 288.05 | |||||
| Price-to-Projected-FCF | 1.96 | |||||
| Price-to-Median-PS-Value | 2.56 | |||||
| Price-to-Graham-Number | 6.28 | |||||
| Earnings Yield (Greenblatt) % | 4.35 | |||||
| FCF Yield % | 0.41 | |||||
| Forward Rate of Return (Yacktman) % | -12.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jubilant Pharmova Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 67,987 | ||
| EPS (TTM) (₹) | 34.8 | ||
| Beta | 1.6 | ||
| Volatility % | 41.78 | ||
| 14-Day RSI | 61.79 | ||
| 14-Day ATR (₹) | 52.703719 | ||
| 20-Day SMA (₹) | 1109.5375 | ||
| 12-1 Month Momentum % | 111.65 | ||
| 52-Week Range (₹) | 319.3 - 1247 | ||
| Shares Outstanding (Mil) | 158.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jubilant Pharmova Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jubilant Pharmova Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Jubilant Pharmova Ltd Frequently Asked Questions
What is Jubilant Pharmova Ltd(BOM:530019)'s stock price today?
The current price of BOM:530019 is ₹1151.90. The 52 week high of BOM:530019 is ₹1247.00 and 52 week low is ₹319.30.
When is next earnings date of Jubilant Pharmova Ltd(BOM:530019)?
The next earnings date of Jubilant Pharmova Ltd(BOM:530019) is 2024-11-29 Est..
Does Jubilant Pharmova Ltd(BOM:530019) pay dividends? If so, how much?
The Dividend Yield %  of Jubilant Pharmova Ltd(BOM:530019) is 0.43% (As of Today), Highest Dividend Payout Ratio of Jubilant Pharmova Ltd(BOM:530019) was 0.41. The lowest was 0.06. And the median was 0.12. The  Forward Dividend Yield % of Jubilant Pharmova Ltd(BOM:530019) is 0.43%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers